Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
MarketBeat on MSN2d
What Does the Future Hold for Eli Lilly?Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.
The biotech has named Jamie Coleman its chief commercial officer, per a Monday announcement, putting her in charge of the ...
Newly-launched obesity company Kailera Therapeutics has announced the appointment of Jamie Coleman as chief commercial ...
Cardinal Health had $210 billion in pharmaceutical and specialty drugs sales in fiscal 2024, up 11% year-over-year, helped in large part by GLP-1 sales. In Q4, segment sales rose 13% to $55 billion, ...
Minnesota Attorney General Keith Ellison says his office has settled with the last of the three largest insulin manufacturers ...
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Alibaba Group Holding Ltd. (BABA), ...
Plus: How AI propelled Nvidia up the list and other insights from this year's survey of corporate reputations.
Novo Nordisk’s amycretin shows 22% weight loss over 36 weeks, potentially surpassing Eli Lilly’s Zepbound. Further trials are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback